title: Clinical potential of a silk sericin-releasing bioactive wound dressing for the treatment of split-thickness skin graft donor sites.
abstract: OBJECTIVE
  An ethyl alcohol-precipitated silk sericin/PVA scaffold that controlled the release of silk sericin was previously developed and applied for the treatment of full-thickness wounds in rats and demonstrated efficient healing. In this study, we aimed to further evaluate the clinical potential of this scaffold, hereafter called "silk sericin-releasing wound dressing", for the treatment of split-thickness skin graft donor sites by comparison with the clinically available wound dressing known as "Bactigras®".
  
  
  METHODS
  In vitro characterization and in vivo evaluation for safety of the wound dressings were performed. A clinical trial of the wound dressings was conducted according to standard protocols.
  
  
  RESULTS
  The sericin released from the wound dressing was not toxic to HaCat human keratinocytes. A peel test indicated that the silk sericin-releasing wound dressing was less adhesive than Bactigras®, potentially reducing trauma and the risk of repeated injury upon removal. There was no evidence of skin irritation upon treatment with either wound dressing. When tested in patients with split-thickness skin graft donor sites, the wounds treated with the silk sericin-releasing wound dressing exhibited complete healing at 12 ± 5.0 days, whereas those treated with Bactigras® were completely healed at 14 ± 5.2 days (p = 1.99 × 10(-4)). In addition, treatment with the silk sericin-releasing wound dressing significantly reduced pain compared with Bactigras® particularly during the first 4 postoperative days (p = 2.70 × 10(-5) on day 1).
  
  
  CONCLUSIONS
  We introduce this novel silk sericin-releasing wound dressing as an alternative treatment for split-thickness skin graft donor sites.
authors.affiliation: Bioactive Resources for Innovative Clinical Applications Research Unit, Chulalongkorn University, Bangkok, Thailand.
authors.forename: Tippawan
authors.initials: T
authors.lastname: Siritientong
authors.forename: Apichai
authors.initials: A
authors.lastname: Angspatt
authors.forename: Juthamas
authors.initials: J
authors.lastname: Ratanavaraporn
authors.forename: Pornanong
authors.initials: P
authors.lastname: Aramwit
mesh_terms: D000269:Adhesives; D000328:Adult; D000818:Animals; D001458:Bandages; D002453:Cell Cycle / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D005260:Female; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000378:metabolism; D011446:Prospective Studies; D051381:Rats; D017208:Rats, Wistar; D047030:Sericins / Q000494:pharmacology*; D047011:Silk / Q000494:pharmacology*; D016038:Skin Transplantation / Q000379:methods; D013552:Swine; D014945:Wound Healing / Q000187:drug effects*; D055815:Young Adult
chemical_list: D000269:Adhesives; D047030:Sericins; D047011:Silk; D010100:Oxygen
references.citation: Burns. 2003 Aug;29(5):487-92
references.pmid: 12880731
references.citation: Biotechnol Appl Biochem. 2005 Oct;42(Pt 2):183-8
references.pmid: 15943583
references.citation: Biosci Biotechnol Biochem. 2007 Oct;71(10):2473-7
references.pmid: 17928707
references.citation: Biomaterials. 2005 Jun;26(17):3587-96
references.pmid: 15621249
references.citation: Br J Community Nurs. 2005 Jun;Suppl:S21, S24, S26-7
references.pmid: 15944502
references.citation: Pak J Pharm Sci. 2008 Jan;21(1):45-50
references.pmid: 18166519
references.citation: Am J Surg. 1969 Oct;118(4):521-5
references.pmid: 4898193
references.citation: Int J Pharm. 2006 Apr 26;313(1-2):123-8
references.pmid: 16488564
references.citation: J Hosp Infect. 1999 Dec;43(4):255-64
references.pmid: 10658801
references.citation: Int J Mol Sci. 2010 May 20;11(5):2200-11
references.pmid: 20559510
references.citation: Cells Tissues Organs. 2013;197(3):224-38
references.pmid: 23307034
references.citation: Mol Cell Biochem. 2008 Apr;311(1-2):111-9
references.pmid: 18214642
references.citation: J Biomater Sci Polym Ed. 2009;20(9):1295-306
references.pmid: 19520013
references.citation: Regul Toxicol Pharmacol. 2008 Oct;52(1):35-8
references.pmid: 18177987
references.citation: Nature. 1962 Jan 20;193:293-4
references.pmid: 14007593
references.citation: Biomaterials. 2004 Apr;25(9):1559-67
references.pmid: 14697858
references.citation: Int J Pharm. 2012 Dec 15;439(1-2):175-86
references.pmid: 23022662
references.citation: J Am Acad Dermatol. 2013 Apr;68(4):e117-e126
references.pmid: 21982060
references.citation: Biosci Biotechnol Biochem. 2005 Feb;69(2):403-5
references.pmid: 15725668
references.citation: Cytotechnology. 2002 Nov;40(1-3):3-12
references.pmid: 19003099
references.citation: Int J Biol Macromol. 2003 Nov;33(1-3):75-80
references.pmid: 14599587
references.citation: Clin Dermatol. 1989 Apr-Jun;7(2):55-65
references.pmid: 2667741
references.citation: Toxicol Sci. 1998 Nov;46(1):176-84
references.pmid: 9928681
references.citation: Appl Nurs Res. 1998 Nov;11(4):174-82
references.pmid: 9852660
references.citation: Burns. 1997 Mar;23 Suppl 1:S33-6
references.pmid: 9177900
references.citation: Br J Oral Maxillofac Surg. 2008 Jan;46(1):55-6
references.pmid: 17113690
references.citation: AAPS PharmSciTech. 2011 Jun;12(2):771-81
references.pmid: 21671201
references.citation: J Natl Cancer Inst. 1984 Jun;72(6):1341-7
references.pmid: 6587155
references.citation: Physiol Rev. 2003 Jul;83(3):835-70
references.pmid: 12843410
references.citation: Regul Toxicol Pharmacol. 2008 Oct;52(1):24-34
references.pmid: 18639964